<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306954</url>
  </required_header>
  <id_info>
    <org_study_id>14-256A</org_study_id>
    <nct_id>NCT02306954</nct_id>
  </id_info>
  <brief_title>Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer</brief_title>
  <official_title>Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prometheus Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cytokine Working Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Providence Health &amp; Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the
      first). Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
      Patients assigned to SBRT arm will receive two doses of SBRT on the Wednesday and Friday
      before the Monday on which IL-2 starts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive IL-2 at 600,000 international units per kilogram (kg) by
      intraveneous bolus (IVB) every 8 hours for 14 planned doses with an additional cycle 14 days
      after the first. Responding patients with regressing disease are eligible for up to 6 IL-2
      cycles. Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gray (Gy) on the
      Wednesday and Friday before the Monday on which IL-2 starts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>5 years</time_frame>
    <description>The objective of this study is to compare the response rate among renal cell cancer (RCC) patients of high dose IL-2 to SBRT + IL-2 in patients with metastatic renal cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate in Patients Who Receive SBRT following Progression on IL-2</measure>
    <time_frame>5 years</time_frame>
    <description>Measure the response of SBRT + IL-2 in patients with RCC who have disease progression after high-dose IL-2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>High Dose IL-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
Patients assigned to the IL-2 arm who have disease progression after the first two IL-2 cycles have the option to receive SBRT followed by 2 additional cycles of IL-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose IL-2 and SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before IL-2 starts (the following Monday). Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High Dose IL-2</intervention_name>
    <description>High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.</description>
    <arm_group_label>High Dose IL-2</arm_group_label>
    <arm_group_label>High Dose IL-2 and SBRT</arm_group_label>
    <other_name>Proleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.</description>
    <arm_group_label>High Dose IL-2 and SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of predominant conventional (clear cell) renal cancer

          -  Patients must be â‰¥ 18 years of age

          -  Tumors amenable to SBRT in lungs (central locations preferred), mediastinum, chest
             wall, bones with a soft tissue component (other than long bones), or liver, liver
             hilum and associated lymph nodes (inclusive of immediately adjacent masses), 1 - 3
             foci; no minimum size, but none greater than 7 cm. Patients may have other metastases
             but only a maximum of 3 will be treated

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 72 hours prior to the start of protocol treatment. In addition, women of
             childbearing potential as well as male patients must agree to take appropriate
             precautions to avoid pregnancy

          -  Patients must agree to participate in the Prometheus IL-2 patient registry (PROCLAIM
             registry)

          -  Patients must sign a study-specific consent form

        Exclusion Criteria:

          -  No metastatic site amenable to SBRT

          -  Patients with brain metastases not candidates for radiosurgery alone

          -  Previous radiation to sites proposed for SBRT

          -  Patients with active systemic, pulmonary, or pericardial infection

          -  Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo
             or fetus

          -  Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline
             EKG

          -  Clinically significant underlying pulmonary disease as measured by pulmonary function
             tests

          -  Blood tests within protocol-specified range

          -  Need for chronic steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Curti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Fountain, RN</last_name>
    <phone>(503) 215-2691</phone>
    <email>Christopher.Fountain@Providence.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brenda Fisher, RN</last_name>
    <phone>(503) 215-2613</phone>
    <email>Brenda.Fisher@providence.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Portland Providence Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marka R Crittenden, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Seung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Bader, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Cha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Crocenzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Solhjem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter J. Urba, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Wang-Chesebro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Fountain, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Conlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Ruzich, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://oregon.providence.org/our-services/p/providence-cancer-center/</url>
    <description>Providence Cancer Center</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Cancer</keyword>
  <keyword>High Dose IL-2</keyword>
  <keyword>SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

